Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial

October 19, 2021 By The ASCO Post Staff

Dieter Hörsch, MD, of Germany’s Central Clinic in Bad Berka, discusses phase III results from the SPINET trial, the largest prospective study to date of the somatostatin analog lanreotide autogel. The study suggests that this agent may prove to be an appropriate treatment option for patients with somatostatin receptor–positive bronchopulmonary neuroendocrine tumors, especially typical carcinoids (Abstract 1096O).

Related Content